Biotech · Public company · Nashville, TN, US
Harrow, Inc.
Ticker HROW · SEC CIK 0001360214
Track this companyFree. Adds Harrow, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials74 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- Sham (No Treatment)Phase 3 · Postoperative Ocular InflammationClinicalTrials.gov · fetched Nov 12, 2026
- TRIESENCE (triamcinolone acetonide injectable suspension)Phase 3 · Postoperative Ocular InflammationClinicalTrials.gov · fetched Nov 12, 2026
- Chloroprocaine ophthalmic gel 3%AntisepticClinicalTrials.gov · fetched Nov 12, 2026
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO)Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- Fluorometholone Acetate Ophthalmic Suspension 0.1%Ocular InflammationClinicalTrials.gov · fetched Nov 12, 2026
- Lidocaine Hydrochloride Injection 2%Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- Loteprednol Etabonate Ophthalmic Gel 0.38%Ocular InflammationClinicalTrials.gov · fetched Nov 12, 2026
- Proparacaine Hydrochloride Ophthalmic Solution 0.5%Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- Sham Subconjunctival InjectionDiabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland DysfunctionPHASE4 · RECRUITING · started Jun 1, 2026ClinicalTrials.gov NCT07224529 · fetched Nov 12, 2026
- A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic SurgeryPHASE3 · ENROLLING_BY_INVITATION · started May 25, 2026ClinicalTrials.gov NCT07832552 · fetched Nov 12, 2026
- Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard AnesthesiaPHASE4 · COMPLETED · started May 20, 2026ClinicalTrials.gov NCT07779356 · fetched Nov 12, 2026
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsPHASE4 · ENROLLING_BY_INVITATION · started Mar 31, 2026ClinicalTrials.gov NCT07456826 · fetched Nov 12, 2026
- Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational StudyRECRUITING · started Mar 31, 2026ClinicalTrials.gov NCT07566975 · fetched Nov 12, 2026
- The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-IodinePHASE4 · COMPLETED · started Jul 15, 2023ClinicalTrials.gov NCT05934253 · fetched Nov 12, 2026
- Tolerability Comparison of Flarex to Lotemax SMPHASE4 · COMPLETED · started May 1, 2021ClinicalTrials.gov NCT07588074 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 27, 2026 · fetched Nov 12, 2026